Breadcrumb

Jeffrey  Schlom, Ph.D.

Jeffrey Schlom, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10, Room 8B09
  • Bethesda, MD 20892-1750
  • 240-858-3463
  • js141c@nih.gov

RESEARCH SUMMARY

As Co-Director of the Center for Immuno-Oncology, Dr. Schlom directs a translational research program in cancer immunology and immunotherapy. He has pioneered the use of novel immunotherapeutics, both as monotherapy and in combination therapies, for a range of human cancers. His studies involve the translation of hypothesis-driven preclinical studies to science-driven clinical trials. Dr. Schlom works closely with clinicians in the CIO and with investigators in multiple Laboratories/Branches of the NCI and NIH, and at extramural Cancer Centers. Dr. Schlom also works closely with investigators in multiple Biotech and Pharma companies, via Cooperative Research and Development Agreements, to rapidly translate preclinical findings into agents for clinical studies. Dr. Schlom’s studies involve the design and development of novel therapeutic cancer vaccines, immunocytokines, checkpoint inhibitor monoclonal antibodies, inhibitors of immune suppressive entities, as well as agents and strategies to modify the tumor microenvironment to render tumor cells more susceptible to immune-mediated therapy.

Areas of Expertise

1) cancer immunotherapy 2) vaccines 3) checkpoint inhibitors 4) cancer immunology 5) immune modulation

Publications

Selected Recent Publications

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Hicks KC, Chariou P, Ozawa Y, Minnar C, Knudson KM, Meyer T, Bian J, Cam M, Gameiro SR, Schlom J.
Nat Commun. . 12(1):5151: 5151, 2021.
Full-Text Article
[ Journal Article ]

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa

Tsai Y-T, Strauss J, Toney NJ, Jochems C, Gulley JL, Donahue RN, Schlom J.
J ImmunoTher Cancer . 10(4): e004601, 2022.
Full-Text Article
[ Journal Article ]

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Strauss J, Gatti-Mays M, Cho BC, Hil A, Salas S, McClay E, Redman J, Abdul Sater H, Donahue R, Jochems C, Lamping E, Burmeister A, Marté J, Cordes L, Bilusic M, Karzai F, Ojalvo L, Jehl G, Rolfe PA, Hinrichs CS, Madan R, Schlom J, Gulley JL
J ImmunoTher Cancer. 8(2): e001395, 2020.
Full-Text Article
[ Journal Article ]

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine

Smalley Rumfield C, Pellom ST, Morillon II YM, Jochems C, Schlom J
J ImmunoTher Cancer. 8(1): e000612, 2020.
Full-Text Article
[ Journal Article ]

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

Knudson KM, Hicks KC, Ozawa Y, Gameiro SR, Schlom J
J ImmunoTher Cancer. 8(1): e000493, 2020.
Full-Text Article
[ Journal Article ]

Job Vacancies

Position Degree Required Contact Name Contact Email
Post-doctoral Fellow - Immunology, immunotherapy Ph.D. or equivalent, M.D. or equivalent Jeffrey Schlom js141c@nih.gov

Team

Lajuan Chase
Animal Technician (Contr.)
Lajuan Chase
Postdoctoral Fellow (Visiting Fellow)
Carolina Celades Errando, M.D.
Animal Technician (Contr)
Emily Gonzales
Meg Goswami, PhD
Postdoctoral Fellow (CRTA)
Meg Goswami, Ph.D.
Rachel L. Kazmierski
Biologist (Contr)
Rachel L Kazmierski
Sarah Khelifa
Postdoctoral Fellow (CRTA)
Sarah Khelifa, PhD
Loc H. Le
Scientist (Contr)
Loc H. Le, PhD
Postdoctoral Fellow (CRTA)
Katherine E. Lothstein, PhD
Grace Lui
Post-baccalaureate (pre-CRTA)
Grace Lui
Maria Del Mar Maldonado Montalban
Postdoctoral Fellow (CRTA)
Maria Del Mar Maldonado Montalban, Ph.D.
Marlene Medina Enriquez
Scientist (Contr)
Marlene Medina Enriquez, PhD
Christine M. Minnar
Postdoctoral Fellow (CRTA)
Christine M Minnar, Ph.D.
Michelle Padget
Biologist
Michelle Padget
Dilia Penate-Pacheco
Program Specialist
Dilia Penate-Pacheco
Steffie Pitts
Post-doctoral Fellow (CRTA)
Stephanie C. Pitts, Ph.D.
Lisa K. Poppe
Postdoctoral Fellow (CRTA)
Lisa K Poppe, Ph.D.
Curtis Randolph
Laboratory Technician (Contr.)
Curtis Randolph
Robin Riley
Program Manager
Robin Riley
Nicholas T. Roller
Biologist
Nicholas T Roller
Angela Schwab
Biologist
Angela Schwab
Nicole J. Toney, PhD
Postdoctoral Fellow (CRTA)
Nicole J. Toney, Ph.D.
Yo-Ting Tsai, PhD
Research Fellow
Yo-Ting Tsai, Ph.D.
Debra L. Weingarten
Editor
Debra L Weingarten
Keanan Wright
Biologist (Contr.)
Keanan Wright

News

In Viewpoint: Evolving Issues in Oncology: “Vaccines as an integral component of cancer immunotherapy,” Drs. Jeffrey Schlom and James Gulley describe the opportunities and challenges for vaccine therapies to treat cancers. JAMA. 2018 Dec 4;320(21):2195-2196.

https://pubmed.ncbi.nlm.nih.gov/30419097/

https://jamanetwork.com/journals/jama/fullarticle/2714651

Immunotherapy drug with two targets shows promise against HPV-related cancers. In a Phase 1 clinical trial at the NCI of 43 patients with advanced cancers, the investigational immunotherapy drug bintrafusp alfa shrank the tumors of some patients with advanced human papillomavirus (HPV)-related cancers. “This drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients more than traditional checkpoint therapies,” said the trial's Principal Investigator, Julius Strauss, M.D., Laboratory of Tumor Immunology and Biology, CCR, NCI.

https://www.cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-y-trap-hpv-cancers

Clinical trial tests immunotherapy combination for advanced HPV-associated cancers. Dr. Julius Strauss is leading a study using a combination of 3 immunotherapy drugs to treat HPV+ cancers. [NCT04287868]

https://ccr.cancer.gov/news/article/clinical-trial-tests-immunotherapy-combination-for-advanced-hpv-associated-cancers

New trial evaluates immunotherapy combinations in adults with advanced small bowel and colorectal cancers is being led by Dr. Julius Strauss. [NCT04491955]

https://ccr.cancer.gov/news/article/new-trial-evaluates-immunotherapy-combinations-in-adults-with-advanced-small-bowel-and-colorectal-cancers

Clinical trial will test triple-drug combination against aggressive colon and HPV-associated cancers. Dr. Julius Strauss discusses promising immunotherapy drug for patients with HPV-related cancers. [NCT04708470]

https://ccr.cancer.gov/news/article/clinical-trial-will-test-triple-drug-combination-against-aggressive-colon-and-hpv-associated-cancers